Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets

Kindt, Nadège; Journé, Fabrice; Laurent, Guy; Saussez, Sven

doi:10.3892/ol.2016.4929

Cited by 47 publications

(47 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 3 , 5 , 6 ] Moreover, the overexpression of MIF has been associated to tumor progression, metastasis and unfavorable prognosis in gastric, hepatocellular, pancreatic, and lung cancers, and oral squamous cell carcinoma and metastatic melanoma. [ 3 , 7 , 8 ]…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of macrophage migration inhibitory factor expression in cancer patients

Koh

Kim

2020

Medicine

View full text Add to dashboard Cite

Background: Recent studies showed that Macrophage migration inhibitory factor (MIF) is overexpressed and closely associated with prognosis in cancer patients. The present study was systematically evaluated the prognostic significance of MIF expression in cancer patients. Methods: PubMed, Cochrane library and Scopus were searched for eligible studies up to January 2020. Pooled hazard ratio with confidence interval (CI) was determined to assess the relationship between MIF expression and survival in cancer patients. Results: A total of 8 studies comprising 847 cancer patients were included in this meta-analysis. For overall survival, the pooled hazard ratio was 2.23 (95% CI 1.67–2.99, P < .001). For disease-free survival, the pooled hazard ratio was 2.24 (95% CI 1.69–2.96, P < .001). The results suggested that high expression of MIF was significantly related to poor overall survival and disease-free survival in cancer patients. Conclusion: MIF expression could be a valuable prognostic factor in cancer patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic significance of macrophage migration inhibitory factor expression in cancer patients

Koh

Kim

2020

Medicine

View full text Add to dashboard Cite

show abstract

“…MIF has been reported to be overexpressed in various cancers, including gastric, esophageal, colorectal, liver, pancreatic, ovarian, breast and prostate cancers . Furthermore, MIF overexpression has been found to be related to a poor prognosis in hepatocellular carcinoma, oral squamous cell carcinoma, metastatic melanoma and pancreatic ductal adenocarcinoma …”

Section: Introductionmentioning

confidence: 99%

“…12,13 Furthermore, MIF overexpression has been found to be related to a poor prognosis in hepatocellular carcinoma, oral squamous cell carcinoma, metastatic melanoma and pancreatic ductal adenocarcinoma. 14 However, the exact role of MIF is not clearly understood in SCC of the lung. In this study, we investigated MIF expression as a prognostic factor in SCC of the lung using immunohistochemistry and evaluated the expression of MIF mRNA and protein and the effect of MIF knockdown on the migration in lung SCC cell lines.…”

Section: Introductionmentioning

confidence: 99%

Prognostic role of macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the lung

Koh

Kim

Kim³

et al. 2019

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundMacrophage migration inhibitory factor (MIF) has been shown to play an important role in the inflammatory and immune response in squamous cell carcinoma (SCC). Recent studies have reported that MIF is involved in the tumorigenesis and overexpressed in various cancers. In this study, we assessed the prognostic role of MIF expression in SCC of the lung, and demonstrated the effect of knockdown of MIF on the migration in lung SCC cell lines.MethodsThe relationship between MIF expression and clinicopathological parameters and the prognostic role of MIF expression were evaluated with immunohistochemical staining in 96 patients with SCC of the lung. The expression of MIF mRNA and protein was analyzed by semi‐quantitative polymerase chain reaction and Western blot in lung SCC cell. The effect of knockdown of MIF was assessed by wound healing assay.ResultsThe high percentage of MIF‐positive cells was significantly associated with lymph node metastasis (P = 0.004), and was a poor prognostic factor of disease‐free survival (DFS) (hazard ratio [HR]: 3.125; 95% confidence interval [CI], 1.628–5.998; P = 0.001) and disease‐specific survival (DSS) (HR: 2.303; 95% CI, 1.172–4.525; P = 0.016). Moreover, Kaplan‐Meier analysis showed that SCC patients with a high percentage of MIF‐positive cells had a significantly lower DFS (P = 0.001) and DSS (P = 0.014) than those with a low percentage. Furthermore, wound healing assay revealed that knockdown of MIF resulted in decreased cellular migration.ConclusionMIF is closely associated with tumor progression and could be a prognostic factor in SCC of the lung.

show abstract

“…In addition, evidence generated during the last 15 years has also supported a pro-oncogenic role of MIF in certain types of cancers [29][30][31]. MIF may upregulate several tumorigenic processes, including tumor growth, invasiveness, and angiogenesis [32] primarily, but not exclusively, through its angiogenetic action, its AKT mediated antiapoptotic effects, and the inhibition of p53 function.…”

Section: Mif and Cancermentioning

confidence: 99%

Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?

et al. 2020

View full text Add to dashboard Cite

Neuroblastoma (NB) is the most frequent extracranial pediatric tumor. Despite the current available multiple therapeutic options, the prognosis for high-risk NB patients remains unsatisfactory and makes the disease a clear unmet medical need. Thus, more tailored therapeutic approaches are warranted to improve both the quality of life and the survival of the patients. Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that plays a key role in several diseases, including cancer. Preclinical and clinical studies in NB patients convergently indicate that MIF exerts pro-tumorigenic properties in NB. MIF is upregulated in NB tumor tissues and cell lines and it contributes to NB aggressiveness and immune-escape. To date, there are only a few data about the role of the second member of the MIF family, the MIF homolog d-dopachrome tautomerase (DDT), in NB. Here, we review the preclinical and clinical studies on the role of the MIF family of cytokines in NB and suggest that MIF and possibly DDT inhibitors may be promising novel prognostic and therapeutic targets in NB management.

show abstract

Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets

Cited by 47 publications

References 57 publications

Prognostic significance of macrophage migration inhibitory factor expression in cancer patients

Prognostic significance of macrophage migration inhibitory factor expression in cancer patients

Prognostic role of macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the lung

Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?

Contact Info

Product

Resources

About